| abstract |
The present invention relates to cyclic P1 linkers as factor XIA inhibitors. The present invention provides a compound of formula (Ia): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein all variables are as defined herein. These compounds are selective factor Xia inhibitors or dual inhibitors of FXIa and plasma kallikrein. The invention also relates to pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of thromboembolic and/or inflammatory disorders. |